Publicacións nas que colabora con Antonio Luis Valero Santiago (24)

2024

  1. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 23-32

  2. Global Lung Initiative as Diagnostic Criteria in Asthma-COPD Overlap Syndrome: Prevalence and Disease Characterization in a Real-Life Asthma Cohort

    Journal of investigational allergology & clinical immunology, Vol. 34, Núm. 3, pp. 192-195

  3. The discrepancy in bronchodilator response between ATS/ERS 2021 and 1991 criteria

    Respiratory Medicine, Vol. 226

2023

  1. ALERGODATA: Sentinel Registry of Health Outcomes in Allergic Patients Treated With Biological Therapies at Specialized Allergology Clinics in Spain

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 6, pp. 479-482

  2. Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 281-288

  3. Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 223-231

  4. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti–IL-5 Biologics: A Real-Life Study

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 1, pp. 37-44

  5. Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 294-296

  6. Reply to “Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies”

    Journal of Investigational Allergology and Clinical Immunology

2022

  1. Anxiety and body mass index affect asthma control: data from a prospective Spanish cohort

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 3, pp. 863-866.e1

  2. Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis

    Immunotherapy, Vol. 14, Núm. 9, pp. 683-694

  3. How reliably can algorithms identify eosinophilic asthma phenotypes using non-invasive biomarkers?

    Clinical and Translational Allergy, Vol. 12, Núm. 8

2021

  1. Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 735-750

  2. Immunological parameters as biomarkers of response to MicroCrystalline Tyrosine-adjuvanted mite immunotherapy

    World Allergy Organization Journal, Vol. 14, Núm. 6

2020

  1. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

    Clinical and Translational Allergy

  2. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 7, pp. 1672-1688

  3. Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis

    Immunotherapy, Vol. 12, Núm. 1, pp. 53-62

2019

  1. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

    Journal of Allergy and Clinical Immunology, Vol. 143, Núm. 3, pp. 864-879

  2. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

    Clinical and Translational Allergy, Vol. 9, Núm. 1

  3. MASK (Mobile Airways Sentinel Network), a mobile App with ARIA’s comprehensive solution in Spanish-speaking countries

    Revista Alergia Mexico, Vol. 66, Núm. 2, pp. 263-268